evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it, the risk that the EIB may accelerate the loans under finance contract and its amendment upon the occurrence of customary events of default; the risk that Company may not be able to secure additional capital on attractive terms, if at all. Furthermore, many other important risks factors and uncertainties, including those described in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 24, 2023 under "Item 3.D. Risk Factors" and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers -- the AMF) on April 24, 2023, (a copy of which is available on www.nanobiotix.com) may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contacts

 
                           Nanobiotix 
---------------------------------------------------------------- 
                                 Investor Relations Department 
 Communications Department        Craig West 
 Brandon Owens                    SVP, Investor Relations 
 VP, Communications               +1 (617) 583-0211 
 +1 (617) 852-4835                investors@nanobiotix.com 
 contact@nanobiotix.com 
-------------------------------  ------------------------------- 
                        Media Relations 
---------------------------------------------------------------- 
FR -- Ulysse Communication       Global -- LifeSci Advisors 
 Pierre-Louis Germain             Ligia Vela-Reid 
 + 33 (0) 6 64 79 97 51           +44 (0) 7413825310 
 plgermain@ulysse-communication   Lvela-reid@lifesciadvisors.com 
-------------------------------  ------------------------------- 
 
 
                  Statements of consolidated operations 
        (Amounts in thousands of euros, except per share numbers) 
 
                                          For the year ended December 31, 
                                               2022             2021 
                                         ----------------  --------------- 
Revenues and other income 
Revenues                                               --               10 
Other income                                        4,776            2,637 
                                         ----------------  --------------- 
Total revenues and other income                     4,776            2,647 
                                         ----------------  --------------- 
Research and development expenses                (32,636)         (30,378) 
Selling, general and administrative 
 expenses                                        (17,857)         (19,434) 
Other operating and income expenses                 (985)          (5,414) 
                                         ----------------  --------------- 
Total operating expenses                         (51,478)         (55,226) 
                                         ----------------  --------------- 
Operating income (loss)                          (46,702)         (52,579) 
                                         ----------------  --------------- 
Financial income                                    3,533            6,360 
Financial expenses                               (13,863)            (780) 
                                         ----------------  --------------- 
Financial income (loss)                          (10,329)            5,580 
                                         ----------------  --------------- 
Income tax                                           (10)              (5) 
                                         ----------------  --------------- 
Net loss for the period                          (57,041)         (47,003) 
                                         ================  =============== 
Basic loss per share (euros/share)                 (1.64)           (1.35) 
Diluted loss per share (euros/share)               (1.64)           (1.35) 
 
 
          Statements of consolidated financial position 
    (Amounts in thousands of euros, except per share numbers) 
 
                                               As of December 31, 
                                                2022       2021 
                                              ---------  --------- 
Total non-current assets                          7,412      8,709 
                                              ---------  --------- 
Cash and cash equivalents                        41,388     83,921 
                                              ---------  --------- 
Total current assets                             52,358     93,060 
--------------------------------------------  ---------  --------- 
TOTAL ASSETS                                     59,769    101,769 
--------------------------------------------  ---------  --------- 
Net loss for the period                        (57,041)   (47,003) 
Total shareholders' equity                     (27,045)     26,790 
                                              ---------  --------- 
Total non-current liabilities                    48,878     38,134 
                                              ---------  --------- 
Total current liabilities                        37,936     36,845 
--------------------------------------------  ---------  --------- 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY       59,769    101,769 
--------------------------------------------  ---------  --------- 
 

Attachment

   -- 2023-04-24 -- NBTX -- FY22 Financial Results -- FINAL -- English 

(END) Dow Jones Newswires

April 24, 2023 19:33 ET (23:33 GMT)